ROLE OF HSP90 IN POLARIZED CELL MORPHOGENESIS IN SCEREVISIAE & C ALBICANS
ROLE OF HSP90 IN POLARIZED CELL MORPHOGENESIS IN SCEREVISIAE & C ALBICANS
批准号:
7959725
负责人:
JILL L JOHNSON
金额:
$14.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-01 至 2010-05-31
关键词:
AffectAntibodiesAntineoplastic AgentsAutomobile DrivingCandida albicansCandidiasisCell WallCell divisionCellsClientComputer Retrieval of Information on Scientific Projects DatabaseDevelopmentDrug Delivery SystemsDrug resistanceEventFundingGeneticGoalsGrantGrowthHeat-Shock Proteins 90InfectionInstitutionLaboratoriesLeadLifeMolecularMolecular ChaperonesMorphogenesisMorphologyMutationOncogenicPathogenicityPatientsPharmaceutical PreparationsPhasePhase II Clinical TrialsPlayProductionProteinsRegulationResearchResearch PersonnelResourcesRoleSaccharomyces cerevisiaeSignal PathwaySourceStagingSystemic infectionTemperatureUnited States National Institutes of HealthYeastsbaseimmunogenicimmunogenicityinhibitor/antagonistmouse modelnovelpathogenpolarized cellpreventtumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
The abundant molecular chaperone Hsp90 is critical for the folding and regulation of a specific set of diverse client proteins involved in cell division and differentiation. In the last few years Hsp90 has emerged as a viable anti-cancer drug target since many oncogenic proteins require Hsp90 for function. As proof of concept, Hsp90 inhibitors slow tumor growth and are currently in Phase II clinical trials. In addition to playing a critical role in the growth of certain tumors, Hsp90 is also required for the development of drug-resistant pathogenic yeast infections caused by Candida albicans, since Hsp90 inhibitors slowed or prevented drug resistance. Thus it seems likely that Hsp90 is required for the function of key proteins involved in C. albicans pathogenicity and the adaptation to drug treatment. The overall goals of this proposal are to determine how Hsp90 function differs depending on the life stage of C. albicans. The driving hypothesis is that during the switch to the pathogenic growth phase or during development of drug resistance, activities of Hsp90 will be focused on client proteins essential for these specialized functions.
Specific Aim 1. Characterize the cellular events that lead to cleavage of Candida albicans Hsp90. Patients that survive systemic infections of C. albicans have circulating antibodies against a fragment of Hsp90. Additional studies indicate that antibodies against C. ablicans Hsp90 are protective in treating candidiasis. Another laboratory established that when expressed in S. cerevisiae, C. albicans undergoes cleavage to generate the immunogenic fragments. We will use a genetic approach in yeast to identify conditions that alter production of the immunogenic fragments with the goal of making directed mutations in C. ablicans to determine the effect of altered proteolytic cleavage on infection and immunogenicity in mouse models.
Specific Aim 2. Characterize the interaction of Hsp90 with Hbt1, a protein required for polarized morphogenesis in Saccharomyces cerevisiae. During the hyphal transition, C. albicans undergoes polarized morphogeneis and reorganization of the cell wall. We identified an interaction between Hbt1 and Hsp90 containing mutations that cause slow, temperature sensitive growth accompanied by altered morphology. Our hypothesis is that Hsp90 interacts with Hbt1 in cells under limiting growth conditions or in cells undergoing morphological changes. These studies will provide novel information about the functions of Hsp90 and Hbt1 in cellular signaling pathways.
Specific Aim 3. Understanding the similarities and differences in how Hsp90 interacts with diverse client proteins. In conjunction with co-chaperone proteins, Hsp90 interacts with hundreds of diverse proteins. We will determine whether the activity of diverse Hsp90 client proteins is similarly affected by mutations in Hsp90 and co-chaperones.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Determinants of the Hsp90-client interaction
-
批准号:10670003
-
项目类别:
-
资助金额:$6.1万
-
财政年份:2019
-
负责人:JILL L JOHNSON
-
依托单位:
Determinants of the Hsp90-client interaction
-
批准号:10241422
-
项目类别:
-
资助金额:$28.29万
-
财政年份:2019
-
负责人:JILL L JOHNSON
-
依托单位:
Determinants of the Hsp90-client interaction
-
批准号:10018926
-
项目类别:
-
资助金额:$28.23万
-
财政年份:2019
-
负责人:JILL L JOHNSON
-
依托单位:
Determinants of the Hsp90-client interaction
-
批准号:10458059
-
项目类别:
-
资助金额:$28.5万
-
财政年份:2019
-
负责人:JILL L JOHNSON
-
依托单位:
Diversity Supplement: Determinants of Hsp90-client interaction
-
批准号:10405217
-
项目类别:
-
资助金额:$5.55万
-
财政年份:2019
-
负责人:JILL L JOHNSON
-
依托单位:
ROLE OF HSP90 IN POLARIZED CELL MORPHOGENESIS IN SCEREVISIAE & C ALBICANS
-
批准号:7720363
-
项目类别:
-
资助金额:$9.37万
-
财政年份:2008
-
负责人:JILL L JOHNSON
-
依托单位:
ROLE OF HSP90 IN POLARIZED CELL MORPHOGENESIS IN SCEREVISIAE & C ALBICANS
-
批准号:7609810
-
项目类别:
-
资助金额:$8.28万
-
财政年份:2007
-
负责人:JILL L JOHNSON
-
依托单位:
ROLE OF HSP90 IN POLARIZED CELL MORPHOGENESIS IN SCEREVISIAE & C ALBICANS
-
批准号:7381180
-
项目类别:
-
资助金额:$10.31万
-
财政年份:2006
-
负责人:JILL L JOHNSON
-
依托单位:
COBRE: UID: HSP40 YDJ1/STI1 TARGETING SUBSTRATES HSP90
-
批准号:7170345
-
项目类别:
-
资助金额:$10.92万
-
财政年份:2005
-
负责人:JILL L JOHNSON
-
依托单位:
COBRE: UID: HSP40 YDJ1 & STI1 IN TARGETING SUBSTRATES TO HSP90 FOLDING PATHWAY
-
批准号:7011790
-
项目类别:
-
资助金额:$15.26万
-
财政年份:2004
-
负责人:JILL L JOHNSON
-
依托单位:
MIM44 AND PROTEIN IMPORT INTO YEAST MITOCHONDRIA
-
批准号:2020771
-
项目类别:
-
资助金额:$2.86万
-
财政年份:1996
-
负责人:JILL L JOHNSON
-
依托单位:
MIM44 AND PROTEIN IMPORT INTO YEAST MITOCHONDRIA
-
批准号:2172030
-
项目类别:
-
资助金额:$2.26万
-
财政年份:1995
-
负责人:JILL L JOHNSON
-
依托单位:
MIM44 AND PROTEIN IMPORT INTO YEAST MITOCHONDRIA
-
批准号:2172031
-
项目类别:
-
资助金额:$2.37万
-
财政年份:1995
-
负责人:JILL L JOHNSON
-
依托单位:
海外基金